Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy
Cancers · 09.06.2026 · 18 (12) · 1882
DOI: 10.3390/cancers18121882 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancers, online erschienen am 09.06.2026. Verfasst von John W Figg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Preston A. Wells Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32611, USA. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Adverse childhood events (ACEs) represent a major public health burden in the United States, as exposure to ACEs increases the risk of mental health disorders, cardiovascular disease, obesity, and cancer and can greatly affect quality of life. Although the effects of ACEs on physiology are complex, significant evidence suggests that ACEs may affect the immune system later in life. As the field of immunotherapy gains prominence in cancer treatment, it becomes imperative to explore how ACEs may impact cancer immunotherapy. Brain cancer, especially glioblastoma multiforme (GBM), has a very poor prognosis and remains a challenging disease to treat. Immunotherapy approaches are being actively investigated. To address this, we aim to raise awareness of the potential connection between ACEs, brain cancer, and cancer immunotherapy. Through a review of the current biomedical literature, we synthesized current findings into a commentary on how early-life adversity may influence the immune response within the central nervous system. It is the intention of this commentary to generate hypothesis-driven research within the nascent and emerging field of neuro-psycho-immunology in neuro-oncology. Given that the relationship between ACEs and brain cancer immunotherapy remains vastly understudied, this commentary has significant potential to generate insightful discussions among clinicians and scientists to guide further clinical and basic research towards anticipating which patients stand to receive the most benefit from immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Preston A. Wells Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32611, USA.
- MD/PhD Program, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
- J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
- Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
- Center for Translational Research in Neurodegenerative Diseases, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
- Department of Clinical and Health Psychology, University of Florida, Gainesville, FL 32611, USA.
ORCID-Profile: John W Figg, Julian Mark, Caretia J Washington, Maegan A Cremer, Scott A Cohen, Deidre B Pereira, Ashley P Ghiaseddin
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Figg, J. W., Mark, J., Washington, C. J., Fusco, A., Cremer, M. A., Cohen, S. A., Quintin, S., Pereira, D. B., & Ghiaseddin, A. P. (2026). Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy. Cancers, 18(12), 1882. https://doi.org/10.3390/cancers18121882
Vancouver
Figg JW, Mark J, Washington CJ, Fusco A, Cremer MA, Cohen SA, et al. Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy. Cancers. 2026;18(12):1882. doi:10.3390/cancers18121882
BibTeX
@article{Figg2026,
author = {Figg, John W and Mark, Julian and Washington, Caretia J and Fusco, Anna and Cremer, Maegan A and Cohen, Scott A and Quintin, Stephan and Pereira, Deidre B and Ghiaseddin, Ashley P},
title = {Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1882},
doi = {10.3390/cancers18121882}
}
EUVIMED